Jon Gardner

@ByJonGardner

Senior reporter, BioPharma Dive. Father of 1, husband of 1, son of 2, brother of 2, uncle of 7. Opinions are mine. RTs are not endorsements. Darn good runner.

Vrijeme pridruživanja: studeni 2012.

Tweetovi

Blokirali ste korisnika/cu @ByJonGardner

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ByJonGardner

  1. Prikvačeni tweet
    28. lip 2019.

    1/ "It's always good news for !" is a phrase I began tweeting back in the days when was in a neck-and-neck race with to get the first exon-skipping agent on the market.

    Prikaži ovu nit
    Poništi
  2. prije 19 sati

    That feeling when a two-month old story on the House drug-price bill is the most-read story of the day.

    Poništi
  3. prije 23 sata

    Also surprised to see Novo Nordisk starting P1 trials of a PCSK9 inhibitor .... this year.

    Poništi
  4. prije 23 sata

    Also, this from Novo: P3 initiation of a weekly insulin analogue.

    Poništi
  5. proslijedio/la je Tweet
    4. velj

    conference call music is pretty intense. I feel like I'm in a dark 80s action film.

    Poništi
  6. prije 23 sata

    Novo Nordisk doesn't seem to be especially fazed by the development of hemophilia GTx.

    Poništi
  7. 4. velj

    Somebody needs to tell Brent Saunders that 4.7% is less than half of 9.9%.

    Poništi
  8. 31. sij

    Seem to recall cases of people ignoring quarantine orders during Ebola.

    Poništi
  9. 31. sij

    And of course, tweeting about is not complete without ....

    Prikaži ovu nit
    Poništi
  10. 31. sij

    Last time I felt like this, it was waiting on Vyondys 53. WE know the outcome of that one.

    Prikaži ovu nit
    Poništi
  11. 31. sij
    Prikaži ovu nit
    Poništi
  12. 30. sij

    Dan Skrovonsky on DIAN-TU trial of solanezumab: It's small size "makes it difficult to know what is the truth."

    Poništi
  13. 30. sij

    Dan Skrovonsky: Size of DIAN-TU trial of solanezumab and severity of disease weigh against it, but mutation clearly drives amyloid production and thus removal should show effects. Data still expected Q1.

    Poništi
  14. 30. sij

    Actually, comment came from Dan Skrovonsky, CSO. Voices sound similar on call.

    Poništi
  15. 30. sij

    Ricks: We'll be watching the FDA response to aducanumab, but don't expect a pivot based on that because we've placed our own bets with sola, donanenemab and zagotenemab.

    Poništi
  16. 30. sij

    "Please limit your questions to two per caller, or one two-part question, or two questions with two-thirds of a part each, or ...."

    Poništi
  17. 30. sij

    Tirzepatide clinical update.

    Poništi
  18. 30. sij

    "We do not expect new trials with pegilodecakin."

    Poništi
  19. 30. sij

    How much longer can and others continue to win on volume with price dragging revenue down?

    Poništi
  20. 30. sij

    pipeline dropouts.

    Poništi
  21. 29. sij
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·